ATE520025T1 - Test für morbus-parkinson-therapeutika - Google Patents

Test für morbus-parkinson-therapeutika

Info

Publication number
ATE520025T1
ATE520025T1 AT06848996T AT06848996T ATE520025T1 AT E520025 T1 ATE520025 T1 AT E520025T1 AT 06848996 T AT06848996 T AT 06848996T AT 06848996 T AT06848996 T AT 06848996T AT E520025 T1 ATE520025 T1 AT E520025T1
Authority
AT
Austria
Prior art keywords
parkinson
test
parkin
disease therapeutics
disease
Prior art date
Application number
AT06848996T
Other languages
English (en)
Inventor
Jennifer Johnston
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE520025T1 publication Critical patent/ATE520025T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06848996T 2005-12-12 2006-12-12 Test für morbus-parkinson-therapeutika ATE520025T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74996405P 2005-12-12 2005-12-12
PCT/US2006/047515 WO2007089334A2 (en) 2005-12-12 2006-12-12 Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein

Publications (1)

Publication Number Publication Date
ATE520025T1 true ATE520025T1 (de) 2011-08-15

Family

ID=38179819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06848996T ATE520025T1 (de) 2005-12-12 2006-12-12 Test für morbus-parkinson-therapeutika

Country Status (6)

Country Link
US (2) US20070212679A1 (de)
EP (1) EP1969367B1 (de)
JP (1) JP2009519040A (de)
AT (1) ATE520025T1 (de)
CA (1) CA2632657A1 (de)
WO (1) WO2007089334A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632657A1 (en) * 2005-12-12 2007-08-09 Elan Pharmaceuticals, Inc. Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
US8017348B1 (en) 2005-12-12 2011-09-13 Elan Pharma International Limited Assay for Parkinson's Disease therapeutics
EP2170888B1 (de) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purinderivate und ihre verwendung als modulatoren des toll-like-rezeptors 7
EP2243033B1 (de) * 2008-01-31 2012-06-06 Elan Pharma International Limited Thermischer denaturierungsscreeningtest zur identifizierung von verbindungskandidaten zur prävention und behandlung von morbus parkinson
US20100021941A1 (en) * 2008-07-25 2010-01-28 Progenra, Incorporated Methods of identifying modulators of ubiquitin ligases
ES2418459B1 (es) * 2008-10-09 2014-08-12 Universitat Autònoma De Barcelona Relacionando agregación proteica con supervivencia de levadura
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
JP6814991B2 (ja) * 2016-02-01 2021-01-20 学校法人順天堂 パーキン活性化剤のスクリーニング法
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
EP1262557B1 (de) * 2000-02-24 2006-10-18 Boehringer Ingelheim International GmbH Das parkin-protein als ubiquitinligase
US20040198650A1 (en) * 2001-03-29 2004-10-07 Poul Jensen Means for inhibiting proteolytical processing of parkin
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Pael受容体、Pael受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
US7070940B2 (en) * 2002-07-18 2006-07-04 Aventis Pharma S.A. Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
CA2632657A1 (en) * 2005-12-12 2007-08-09 Elan Pharmaceuticals, Inc. Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein

Also Published As

Publication number Publication date
JP2009519040A (ja) 2009-05-14
CA2632657A1 (en) 2007-08-09
US20070212679A1 (en) 2007-09-13
US20090317825A1 (en) 2009-12-24
WO2007089334A3 (en) 2008-01-10
EP1969367A2 (de) 2008-09-17
WO2007089334A2 (en) 2007-08-09
EP1969367B1 (de) 2011-08-10

Similar Documents

Publication Publication Date Title
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
MX358705B (es) Agentes de union de esclerostina.
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
MA30474B1 (fr) Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee.
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
MA29836B1 (fr) Proteines de fusion avec l'albumine
BRPI0516857A (pt) dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico
DE602008005596D1 (de) Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
NO20043245L (no) Bindingsproteiner som biosensorer
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
ATE485359T1 (de) Verwendung von grenzflächenaktiven, nicht- enzymatischen proteinen für die textilwäsche
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
MX2007007259A (es) Inhibidores de homodimerizacion de myd88.
WO2007089334A3 (en) Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
ATE306498T1 (de) Von zellen präsentierte peptide
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
DE602006017882D1 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties